ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Hideki Izumi, Hisamichi Yoshii, Masaya Mukai, Eiji Nomura, Naoki Yazawa, Daisuke Furukawa, Yoshihito Masuoka, Misuzu Yamada, Taro Mashiko, Takuma Tajiri, Toshio Nakagohri, Hiroyasu Makuuchi
Background: Pancreatic carcinoma has a poor prognosis. It is important to focus on early detection and treatment for improvement of the prognosis. Understanding the characteristics of TS1 pancreatic carcinoma (≤2 cm) could improve the treatment outcome of pan…
Ola Røkke, Thomas Heggelund, Jurate Saltyte Benth, Marianne Steffensen Røkke, Kjell Kåre Øvrebø
Purpose: To identify clinical predictors of recurrence of colorectal cancer after curative surgical treatment. Methods: Retrospective follow-up-study of 925 consecutive patients treated with R0-resection for colorectal cancer Stage I, II and III from 1990 unt…
Márcia Lúcia Sousa Dias Alves, Maria Helena de Agrela Gonçalves Jardim, Bárbara Pereira Gomes, 1 1
People with oncological disease demonstrate, in addition to the side effects of the treatments, the future uncertainties and suffering, having this pathology an impact on self-image, in interpersonal relationships, the meanings and ways of life. We design the…
Bangaly Traore, Leopold Lamah
Aim : The main aim of this study was to evaluate outcomes after surgical treatment of skin cancer. Methods : This retrospective cohort study concerned 46 patients who presented 43 skin cancers lesions surgically treated at surgical oncology unit, Conakry Univ…
Shigeru Fujisaki, Motoi Takashina, Kenichi Sakurai, Ryouichi Tomita, Tadatoshi Takayama
Primary undifferentiated pleomorphic sarcoma (UPS) of the small intestine is extremely rare. The prognosis of UPS is basically poor, and particular, when accompanied with metastatic lesions. This paper reports the case of a long-term survivor of primary UPS o…
Hamza Abbas, Alia M. Attia, Ahmed A. S. Salem, Gamal Amira, Adel Gabr, Reham El Morshedy, Mohamed Hamdy
Purpose: Our prospective phase II trial aims to show the feasibility of adjuvant paclitaxel-based concurrent chemoradiotherapy (CCRT) following doxorubicin and cyclophosphamide (AC) to get the survival benefit of taxanes addition and avoid delay of radiothera…
Yasser El Ghamrini, Ahmed Morad, Hossam Elsadek, Ahmed Ezzat
Background: Integration of neoadj u vant chemotherapy (NCT) in early 70s resulted that many LABC tumors become resectable but with total mastectomy especially those with partial response, oncoplastic techniques give better oncological outcome with better cosm…
Hiromi Fuchikami, Naoko Takeda, Kazuhiko Sato
Background: Preoperative identification of patients with extensive lymph node metastasis (LNM) is important for safe omission of axillary lymph node dissection (ALND) in sentinel node (SN) - positive (SN+) breast cancer patients. Methods: We evaluated retrosp…
Toshikazu Moriwaki, Tetsuya Eto, Akihito Tsuji, Nobushige Kakinoki, Mitsuo Shimada, Takashi Maeba, Hiroaki Hatano, Ikuo Takahashi, Hiroyasu Ishida, Kazuho Ikeda, Yoshiaki Bando, Ichinosuke Hyodo
Fluoropyrimidine combined with bevacizumab is commonly used in elderly patients with metastatic colorectal cancer worldwide. However, the propor tion of elderly patients who discontinued treatment due to toxicities was higher than that of younger patients. Th…
Yuki Katsuya, Yuichiro Takeda, Go Naka, Haruhito Sugiyama
Background: Pemetrexed (PEM) is an efficacious multi-targeted antifolate with acceptable toxicities for non-squamous non-small cell lung cancer (non-Sq NSCLC). However, in the clinical setting, PEM has more severe adverse effects than those reported. The aim…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).